Germany
I am an M&A, Strategy, and Business Development leader with 10+ years of experience delivering complex transactions, shaping corporate strategy, and driving integration and transformation initiatives across the life sciences and pharmaceutical sectors. At Sartorius, I manage global end-to-end M&A projects - leading target screening, valuation, financial and operational due diligence, operating model design, and seamless post-merger integration. I collaborate closely with the Executive Board and senior leaders across regions while guiding cross-functional teams of up to 100 colleagues in strategy development and execution. My work directly supports portfolio growth, strategic positioning, and long-term value creation
• Led global end-to-end M&A processes, including target screening, valuation, and due diligence. • Collaborated with the Executive Board to drive strategic portfolio direction and market expansion initiatives. • Managed cross-functional teams of up to 100 colleagues to ensure coordinated strategy development and later execution. • Designed target operating models and portfolio roadmaps to accelerate synergy realization and ensure value creation.
• Led numerous carve-out workstreams for a major life sciences client, focusing on the target operating model of a manufacturing plant. • Supported the separation of a business unit across 135+ countries, identifying regulatory barriers and coordinating efforts. • Developed integration and separation playbooks for clients in pharmaceuticals, chemicals, and energy sectors.
• Supported a telecommunications provider in defining innovative IoT business models tailored for the life sciences sector. • Contributed to the organizational restructuring of a cardiac pacemaker manufacturer post-international acquisition. • Conducted thorough market-entry strategy evaluations for a Japanese chemical manufacturer entering the German automotive supplier market. • Developed KPI-based reporting tools to effectively track and enhance restructuring performance.
• Identified and assessed startup partners to support Merck’s Industry 4.0 innovation initiatives. • Conducted financial NPV evaluations for licensing deals, enhancing portfolio value. • Developed business models that aligned with strategic goals, fostering innovation within the lab business.
• Conducted KPI analyses of competitor product portfolios to facilitate a significant asset swap. • Developed tracking tools for royalty payments by indication and stage, enhancing financial oversight. • Contributed to white papers on asset versus share deals, supporting strategic decision-making.